GLOBAL REACH: The generic drugmaker is hopeful that its Desud Plus would be included in US public health insurance plans, further driving growth next year
Date: Nov 22, 2019
By: Kao Shih-ching / Staff reporter
Lotus Pharmaceuticals Co (美時化學製藥) yesterday gave an upbeat outlook for global sales of its generic drugs this quarter, as its marketing network now covers more than 130 countries.
Third-quarter sales grew 24.5 percent from a year earlier to NT$1.96 billion (US$64.21 million), mainly boosted by robust US sales of its buprenorphine/naloxone tablets, which are sold under the name Desud Plus, for the treatment of narcotic addiction, the generic drugmaker said.
The company’s sales of lenalidomide for treatment of blood cancer also advanced in Europe, while sales of other drugs in other regions — including Southeast Asia and Africa — also reported rapid growth, Lotus acting spokeswoman Nadiya Chen (陳荻雅) told the Taipei Times by telephone.
International sales used to account for only a single-digit percent of its total sales, but they had risen to about 21 percent as of the end of September, Chen said. [FULL STORY]